Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE Atherosclerosis plus Pub Date : 2024-04-04 DOI:10.1016/j.athplu.2024.03.001
Yu Kataoka , Satoshi Kitahara , Sayaka Funabashi , Hisashi Makino , Masaki Matsubara , Miki Matsuo , Yoko Omura-Ohata , Ryo Koezuka , Mayu Tochiya , Tamiko Tamanaha , Tsutomu Tomita , Kyoko Honda-Kohmo , Michio Noguchi , Kota Murai , Kenichiro Sawada , Takamasa Iwai , Hideo Matama , Satoshi Honda , Masashi Fujino , Kazuhiro Nakao , Teruo Noguchi
{"title":"Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial","authors":"Yu Kataoka ,&nbsp;Satoshi Kitahara ,&nbsp;Sayaka Funabashi ,&nbsp;Hisashi Makino ,&nbsp;Masaki Matsubara ,&nbsp;Miki Matsuo ,&nbsp;Yoko Omura-Ohata ,&nbsp;Ryo Koezuka ,&nbsp;Mayu Tochiya ,&nbsp;Tamiko Tamanaha ,&nbsp;Tsutomu Tomita ,&nbsp;Kyoko Honda-Kohmo ,&nbsp;Michio Noguchi ,&nbsp;Kota Murai ,&nbsp;Kenichiro Sawada ,&nbsp;Takamasa Iwai ,&nbsp;Hideo Matama ,&nbsp;Satoshi Honda ,&nbsp;Masashi Fujino ,&nbsp;Kazuhiro Nakao ,&nbsp;Teruo Noguchi","doi":"10.1016/j.athplu.2024.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet.</p></div><div><h3>Methods</h3><p>The OPTIMAL study was a prospective randomized controlled study to compare the efficacy of 48-week continuous glucose monitoring- and HbA1c-guided glycemic control on near infrared spectroscopty (NIRS)/intravascular ultrasound (IVUS)-derived plaque measures in 94 statin-treated patients with T2D (jRCT1052180152, UMIN000036721). Of these, 78 patients with evaluable serial NIRS/IVUS images were analyzed to compare plaque measures between those treated with (n = 16) and without GLP-1RAs (n = 72).</p></div><div><h3>Results</h3><p>All patients received a statin, and on-treatment LDL-C levels were similar between the groups (66.9 ± 11.6 vs. 68.1 ± 23.2 mg/dL, p = 0.84). Patients receiving GLP-1RAs demonstrated a greater reduction of HbA1c [-1.0 (-1.4 to −0.5) vs. −0.4 (-0.6 to −0.2)%, p = 0.02] and were less likely to demonstrate a glucose level &gt;180 mg/dL [-7.5 (-14.9 to −0.1) vs. 1.1 (-2.0 - 4.2)%, p = 0.04], accompanied by a significant decrease in remnant cholesterol levels [-3.8 (-6.3 to −1.3) vs. −0.1 (-0.8 - 1.1)mg/dL, p = 0.008]. On NIRS/IVUS imaging analysis, the change in percent atheroma volume did not differ between the groups (−0.9 ± 0.25 vs. −0.2 ± 0.2%, p = 0.23). However, GLP-1RA treated patients demonstrated a greater frequency of maxLCBI<sub>4mm</sub> regression (85.6 ± 0.1 vs. 42.0 ± 0.6%, p = 0.01). Multivariate analysis demonstrated that the GLP-1RA use was independently associated with maxLCBI<sub>4mm</sub> regression (odds ratio = 4.41, 95%CI = 1.19–16.30, p = 0.02).</p></div><div><h3>Conclusions</h3><p>In statin-treated patients with T2D and CAD, GLP-1RAs produced favourable changes in lipidic plaque materials, consistent with its stabilization.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667089524000099/pdfft?md5=62075046dc5f7ac01d5b74dc5d82f5dd&pid=1-s2.0-S2667089524000099-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667089524000099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims

Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet.

Methods

The OPTIMAL study was a prospective randomized controlled study to compare the efficacy of 48-week continuous glucose monitoring- and HbA1c-guided glycemic control on near infrared spectroscopty (NIRS)/intravascular ultrasound (IVUS)-derived plaque measures in 94 statin-treated patients with T2D (jRCT1052180152, UMIN000036721). Of these, 78 patients with evaluable serial NIRS/IVUS images were analyzed to compare plaque measures between those treated with (n = 16) and without GLP-1RAs (n = 72).

Results

All patients received a statin, and on-treatment LDL-C levels were similar between the groups (66.9 ± 11.6 vs. 68.1 ± 23.2 mg/dL, p = 0.84). Patients receiving GLP-1RAs demonstrated a greater reduction of HbA1c [-1.0 (-1.4 to −0.5) vs. −0.4 (-0.6 to −0.2)%, p = 0.02] and were less likely to demonstrate a glucose level >180 mg/dL [-7.5 (-14.9 to −0.1) vs. 1.1 (-2.0 - 4.2)%, p = 0.04], accompanied by a significant decrease in remnant cholesterol levels [-3.8 (-6.3 to −1.3) vs. −0.1 (-0.8 - 1.1)mg/dL, p = 0.008]. On NIRS/IVUS imaging analysis, the change in percent atheroma volume did not differ between the groups (−0.9 ± 0.25 vs. −0.2 ± 0.2%, p = 0.23). However, GLP-1RA treated patients demonstrated a greater frequency of maxLCBI4mm regression (85.6 ± 0.1 vs. 42.0 ± 0.6%, p = 0.01). Multivariate analysis demonstrated that the GLP-1RA use was independently associated with maxLCBI4mm regression (odds ratio = 4.41, 95%CI = 1.19–16.30, p = 0.02).

Conclusions

In statin-treated patients with T2D and CAD, GLP-1RAs produced favourable changes in lipidic plaque materials, consistent with its stabilization.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胰高血糖素样肽-1 类似物与他汀类药物治疗的 2 型糖尿病冠心病患者冠状动脉粥样斑块的脱脂作用:OPTIMAL 随机临床试验的预设子分析
背景和目的随机临床试验证明,胰高血糖素样肽-1类似物(GLP-1RA)能够减少2型糖尿病(T2D)患者的动脉粥样硬化性心血管疾病事件。方法OPTIMAL研究是一项前瞻性随机对照研究,目的是在94名经他汀治疗的T2D患者中比较48周连续血糖监测和HbA1c指导的血糖控制对近红外光谱(NIRS)/血管内超声(IVUS)得出的斑块测量结果的疗效(jRCT1052180152,UMIN000036721)。结果所有患者都接受了他汀类药物治疗,两组患者治疗时的 LDL-C 水平相似(66.9 ± 11.6 vs. 68.1 ± 23.2 mg/dL,p = 0.84)。接受 GLP-1RAs 治疗的患者 HbA1c 下降幅度更大 [-1.0 (-1.4 to -0.5) vs. -0.4 (-0.6 to -0.2)%,p = 0.02],出现血糖水平 >180 mg/dL [-7.5 (-14.9 to -0.1) vs. 1.1 (-2.0 - 4.2)%, p = 0.04],同时残余胆固醇水平显著下降[-3.8 (-6.3 to -1.3) vs. -0.1 (-0.8 - 1.1)mg/dL, p = 0.008]。在 NIRS/IVUS 成像分析中,两组之间动脉粥样斑块体积百分比的变化没有差异(-0.9 ± 0.25 vs. -0.2 ± 0.2%,p = 0.23)。然而,GLP-1RA 治疗患者的 maxLCBI4mm 回归率更高(85.6 ± 0.1 vs. 42.0 ± 0.6%,p = 0.01)。多变量分析表明,GLP-1RA 的使用与 maxLCBI4mm 的消退独立相关(几率比 = 4.41,95%CI = 1.19-16.30,p = 0.02)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Atherosclerosis plus
Atherosclerosis plus Cardiology and Cardiovascular Medicine
CiteScore
2.60
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA) Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? Coronary artery calcification score and 19 biomarkers on cardiovascular events; a 10-year follow-up DanRisk substudy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1